Ethypharm, Inc.

Laboratoires Des Produits Ethiques Ethypharm

Laboratoires Des Products Ethiques Ethypharm

Ethypharm Sa

Laboratories Des Produits Ethiques Ethypharim

Laboratories Des Produits Ethiques Ethypharm

Pascal Oury

Pascal Suplie

Patrice Debregeas

G&eacute;rard Leduc

Catherine Herry

Bruno Criere

George Bobotas

Philippe Chenevier

Gerard Leduc

Keith S Rotenberg

Patrice Romain

Dominique Marechal

Johnatan Bacon

Didier Hoarau

Guillaume Benoist

Vincent Billoet

Yann Prevost

Vincent Cailly-Dufestel

Jonathan Bacon

Joseph Duvochel

Francoise Vauzelle-Kervroedan

Maryline Boyer

Françoise Vauzelle-Kervroedan

Gérard Leduc

The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.

Reduction of opioid blood fluctuations

The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.

Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same

The present invention relates to a fentanyl coated tablet and to the method for the preparation thereof.

Sublingual coated tablet of fentanyl

An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.

Multilayer orally disintegrating tablet

Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.

Pharmaceutical composition containing fenofibrate and method for the preparation thereof

Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.

Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion

A pharmaceutical formulation of a gastric proton pump inhibitor, with the exception of omeprazole, is disclosed. The formulation is in the form of microgranules insoluble in gastric fluid having improved stability over time. The formulation comprises several hydrophobic substances chosen in order to increase the stability of the active principle while obtaining the desired dissolution profile.

Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations

The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.

Orally-dispersible multilayer tablet

The present invention concerns a novel sustained-release oral formulation of morphine sulphate in the form of microgranules. Each microgranule comprises a neutral support grain coated with an active layer and with a sustained-release layer, characterized in that the sustained-release layer contains a copolymer of methacrylic acid and of methyl methacrylate ester, the relative proportion of the free carboxyl groups and of the ester groups of which is equal to 0.5 approximately, and a silica exhibiting a hydrophobic character. The present invention also concerns a process for preparing these microgranules which is carried out entirely in aqueous medium by emplacing on neutral support grains.

Morphine sulphate microgranules, method for preparing same and compositions containing same

The invention concerns a device for producing granules, in particular pharmaceutical granules, comprising a drum ( ) with peripheral apertures ( ) and a member ( ) feeding the drum with coating or fixing substance. The drum ( ) comprises mutually parallel sections ( ) defining between them the apertures ( ).

Device for coating granules to be administered orally

Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).

Sustained-release microgranules containing diltiazem as active principle

The invention concerns omeprazole microgranules each comprising an active layer containing the active principle, and an outer gastroprotecting layer containing a gastroprotecting agent, characterized in that the omeprazole is combined with at least a hydrophobic substance.

Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations

The present invention relates to a novel oral immediate-release morphine sulfate formulation in the form of microgranules. Each microgranule comprises a neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose, which represents 10 to 50% by weight of the morphine sulfate/binder mixture. The present invention also relates to a process for the preparation of these microgranules which is carried out entirely in aqueous medium on neutral support grains. The present invention finally relates to the pharmaceutical preparations comprising the microgranules according to the invention.

Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations

The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.

Growing community of inventors

Le Chesnay, France

Pascal Oury